ICH Q5 series guidelines on quality of biotechnological products

Target entity: ICH Q5 series guidelines on quality of biotechnological products
Context triple: [ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, relatedTo, ICH Q5 series guidelines on quality of biotechnological products]

• A. ICH Q11 Development and Manufacture of Drug Substances
  ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
• B. ICH Q8 Pharmaceutical Development
  ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
• C. ICH Q3A Impurities in New Drug Substances
  ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
• D. ICH Q1 Stability Testing of New Drug Substances and Products
  ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
• E. ICH Q10 Pharmaceutical Quality System
  ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: ICH Q5 series guidelines on quality of biotechnological products
Target entity description: The ICH Q5 series comprises internationally harmonized guidelines that define quality, characterization, manufacturing, and control requirements for biotechnological and biological products to ensure their safety, purity, and consistency.

• A. ICH Q11 Development and Manufacture of Drug Substances
  ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
• B. ICH Q8 Pharmaceutical Development
  ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
• C. ICH Q3A Impurities in New Drug Substances
  ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
• D. ICH Q1 Stability Testing of New Drug Substances and Products
  ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
• E. ICH Q10 Pharmaceutical Quality System
  ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
• F. None of above. chosen